A Crucial Step! World's First Successful Gene - Edited Pig Lung Transplant into a Brain - Dead Patient
Release time:
2025-09-05
Recently, the international authoritative journal Nature Medicine published a paper announcing the completion of the world's first pre - clinical trial of transplanting a gene - edited pig lung into a brain - dead human. This achievement offers a breakthrough solution to the global shortage of lung transplant donors and is hailed by international experts as a "milestone" in the field of xenogeneic organ transplantation.
Six Gene Edits + Nine - Day Function Maintenance: Key Technological Breakthrough
This trial was led by the team of Professor He Jianxing from the First Affiliated Hospital of Guangzhou Medical University. The research team selected a Bama miniature pig with six gene edits as the donor and transplanted its left lung into a brain - dead patient, mimicking the common single - lung transplant procedure in clinical practice.
Post - operative monitoring data showed that the transplanted lung successfully maintained ventilation and gas exchange functions for up to nine days, with no hyperacute rejection reaction occurring during this period. Synchronous pathogen monitoring also detected no signs of active infection. This outcome indicates that gene - edited pig organs can function stably in the human body in the short term, laying the groundwork for extending their survival time in the future.
Ethics First + Technological Iteration: The Path from Laboratory to Clinic
As a cutting - edge area in global medical research, the ethical compliance of xenogeneic organ transplantation has drawn significant attention. The research team emphasized that this trial strictly adhered to China's laws, regulations, and ethical guidelines. The plan passed multiple - level reviews, including those by the hospital's ethics committee, and was under full - time supervision. The subject was a patient with severe traumatic brain injury. After multiple independent assessments confirmed brain death, the patient's family voluntarily participated in the study to support medical progress. The trial ended on the ninth day at the family's request.
"The global demand for organ transplants is increasing with the aging population, and xenotransplantation is seen as a key solution to the donor shortage," the research team stated. In the next step, they will focus on optimizing gene - editing strategies and anti - rejection treatment protocols to prolong the survival of transplanted organs. Additionally, they will promote the application of the self - developed "tubeless technology" in the trials to reduce the damage to donor lungs caused by mechanical ventilation and accelerate the transition to clinical use.
International Recognition: The "Milestone" Significance in the Challenge of Lung Transplantation
Compared with previous xenogeneic kidney, heart, and liver transplants, lung transplantation is considered more challenging because the lungs are constantly exposed to the external air, making their physiological balance more fragile. Beatrice Domínguez - Hill, the director of the Spanish National Transplant Organization, commented that China's progress in the most difficult area of lung transplantation "is an important milestone in relevant research."
This achievement not only validates the feasibility of gene - editing technology in xenogeneic lung transplantation but also marks China's shift from a follower to a leader in this field. With further research, xenogeneic lung transplantation may bring new hope to countless patients awaiting organ transplants.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
